31,199 Shares in Elanco Animal Health Incorporated $ELAN Bought by Aaron Wealth Advisors LLC

Aaron Wealth Advisors LLC purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 31,199 shares of the company’s stock, valued at approximately $628,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Primecap Management Co. CA increased its stake in shares of Elanco Animal Health by 3.1% during the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after buying an additional 1,543,279 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in Elanco Animal Health by 1.9% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company’s stock worth $167,826,000 after acquiring an additional 292,655 shares in the last quarter. Brandes Investment Partners LP increased its position in shares of Elanco Animal Health by 11.3% in the 2nd quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after purchasing an additional 820,901 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock valued at $46,192,000 after purchasing an additional 2,468,122 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was bought at an average cost of $21.30 per share, with a total value of $213,000.00. Following the transaction, the director owned 131,773 shares of the company’s stock, valued at $2,806,764.90. The trade was a 8.21% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Rajeev A. Modi bought 4,500 shares of the stock in a transaction on Thursday, December 11th. The stock was bought at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the purchase, the insider directly owned 123,082 shares in the company, valued at approximately $2,625,339.06. The trade was a 3.79% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 43,450 shares of company stock worth $937,883. Corporate insiders own 0.89% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $22.12 on Friday. The firm’s fifty day simple moving average is $21.87 and its 200-day simple moving average is $18.28. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $23.70. The stock has a market capitalization of $10.99 billion, a price-to-earnings ratio of 368.73, a PEG ratio of 3.38 and a beta of 1.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. Elanco Animal Health’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. UBS Group boosted their target price on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Stifel Nicolaus increased their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Barclays assumed coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They set an “overweight” rating and a $30.00 target price for the company. Finally, JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price target for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.78.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.